Glucocorticoid receptor antagonists

Current Topics in Medicinal Chemistry

Volumn 8, Issue 9, 2008, Pages 813-838

  Clark, Robin D ^a  

^a Corcept Therapeutics ^*  (United States)

Author keywords

Glucocorticoid receptor anatagonist; GR antagonist; Mifepristone; Nuclear receptor

Indexed keywords

11BETA (1,3 BENZODIOXOL 5 YL) 17BETA HYDROXY 17ALPHA (1 PROPYNYL)ESTRA 4,9 DIEN 3 ONE; 3ALPHA, 5BETA TETRAHYDROCORTISOL; A 348441; AMINOGLUTETHIMIDE; ANTIDEPRESSANT AGENT; ANTIGLAUCOMA AGENT; AZADECALIN DERIVATIVE; CHROMENE DERIVATIVE; CP 409069; CP 47255; CYPROTERONE ACETATE; DIHYDROPYRIDINE DERIVATIVE; DIHYDROQUINOLINE DERIVATIVE; FLUOXETINE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ANTAGONIST; KETOCONAZOLE; METYRAPONE; MIFEPRISTONE; MITOTANE; NEUROLEPTIC AGENT; OCTAHYDROPHENANTHRENE DERIVATIVE; OLANZAPINE; ORG 34850; PLACEBO; PYRIMIDINEDIONE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; STEROID HORMONE RECEPTOR BLOCKING AGENT; TRIPHENYLMETHANE DERIVATIVE; UNINDEXED DRUG;

ALZHEIMER DISEASE; BINDING AFFINITY; CLINICAL TRIAL; COCAINE DEPENDENCE; CUSHING SYNDROME; DEPRESSION; DEPRESSIVE PSYCHOSIS; DIABETES MELLITUS; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; FATIGUE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; MENINGIOMA; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; OBESITY; RECEPTOR BLOCKING; REVIEW; SEDATION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN;

DRUG EVALUATION, PRECLINICAL; DRUG THERAPY; HORMONE ANTAGONISTS; HUMANS; PROTEIN BINDING; RECEPTORS, GLUCOCORTICOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 47249123713     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802608784535011     Document Type: Review

References (100)

1. Mohler, M. L.; He, Y.; Wu, Z.; Hong, S.-S.; Miller D. D. Nonsteroidal glucocorticoid receptor antagonists: The race to replace RU-486 for anti-glucocorticoid therapy. Expert Opin. Ther. Patents 2007, 17, 59-80.
2. Coghlan, M. J.; Elmore, S. W.; Kym, P. R.; Kort, M. E. Selective Glucocorticoid Receptor Modulators. Ann. Rep. Med. Chem. 2002, 37, 167-176.
3. Lamberts, S. W.; Koper, J. W.; deJong, F. H.; The endocrine effects of long-term treatment with mifepristone (RU 486). J. Clin. Endocrinol Metab. 1991, 73, 187-191.
4. Grunberg, S. M.; Weiss, M. H.; Russell, C. A.; Spitz, I. M.; Ahmadi, J.; Sadun, A.; Sitruk-Ware, R. Long-term administration of mifepristone (RU486): Clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006, 24, 727-733.
5. Bertagna, X.; Escourolle, H.; Pinquier, J. L.; Coste, J.; Raux-Demay, M. C.; Perles, P.; Silvestre, L.; Luton, J. P.; Strauch, G. Administration of RU 486 for 8 days in normal volunteers: Antiglucocorticoid effect with no evidence of peripheral cortisol deprivation. J. Clin. Endocrinol. Metab. 1994, 78, 375-380.
6. Nihalani, N. D.; Schwartz, T. L. Drug Evaluation: Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression. Exp. Opin. Investig. Drugs 2007, 8, 563-569.
7. Labeur, M; Arzt, E.; Stalla, G. K.; Paez-Perada, M. New perspectives in the treatment of Cushing's syndrome. Current Drug Targets: Immune, Endocrine and Metabolic Disorders 2004, 4, 335-342.
8. Nieman, L. K.; Chrousos, G. P.; Kellner, C.; Spitz, I. M.; Nisula, B. C.; Cutler, G. B.; Merriam, G. R.; Bardin, C. W.; Loriaux, D. L. Successful Treatment of Cushing's Syndrome with the Glucocorticoid Antagonist RU 486. J. Clin. Endocrinol. Metab. 1985, 61, 536-540.
9. Chu, J. W.; Matthias, D. F.; Belanoff, J.; Schatzberg, A.; Hoffman, A. R.; Feldman, D. Successful Long-Term Treatment of Refractory Cushing's Disease with High-Dose Mifepristone (RU 486). J. Clin. Endocrinol. Metab. 2001, 86, 3568-3573.
10. Reus, V. I.; Wolkowitz, O. M. Antiglucocorticoid drugs in the treatment of depression. Expert. Opin. Investig. Drugs 2001, 10, 1789-1796.
11. Gold, P. W.; Drevets, W. C.; Charney, D. S. New Insights into the Role of Cortisol and the Glucocorticoid Receptor in Severe Depression. Biol. Psychiatry 2002, 52, 381-385.
12. Belanoff, J. K.; Kalehzan, M.; Sund, B.; Fleming Ficek, S. K.; Schatzberg, A. F. Cortisol Activity and Cognitive Changes in Psychotic Major Depression. Am. J. Psychiatry 2001, 158, 1612-1616.
13. Belanoff, J. K.; Flores, B. H.; Kalezhan, M.; Sund, B. S.; Schatzberg, A. F. Rapid Reversal of Psychotic Depression Using Mifepristone. J. Clin. Psychopharmacol. 2001, 21, 516-521.
14. Flores, B. H.; Kenna, H.; Keller, J.; Solvason, H. B.; Schatzberg, A. F. Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression. Neuropsychopharmacology 2006, 31, 628-636.
15. DeBattista, C.; Belanoff, J. The use of mifepristone in the treatment of neuropsychiatric disorders. Trends Endocrinol. Metab. 2006, 17, 117-121.
16. Johnson, D. A.; Grant, E. J.; Ingram, C. D.; Gartside, S. E. Glucocorticoid Receptor Antagonists Hasten and Augment Neurochemical Responses to a Selective Serotonin Reuptake Inhibitor Antidepressant. Biol. Psychiatry 2007, 62, 1228-1235.
17. Baxter, J. D. Glucocorticoid hormone action. Pharmacol. Ther. [B] 1976, 2(3), 605-669.
18. Pilkis, S. J.; Granner, D. K. Molecular physiology of the regulation of heptic gluconeogenesis. Am. Rev. Physiol. 1992, 54, 885-909.
19. Opherk, C.; Tronche, F.; Kellendonk, C.; Kohlmüller, D.; Schulze, A.; Schmid, W.; Schütz, G. Inactivation of the Glucocorticoid Receptor in Hepatocytes Leads to Fasting Hypoglycemia and Ameliorates Hyperglycemia in Streptozotocin-Induced Diabetes Mellitus. Mol. Endocrinol. 2004, 18, 1346-1353.
20. Friedman, J. E.; Sun, Y.; Ishizuka, T.; Farrell, C. J.; McCormack, S. E.; Herron, L. M.; Hakimi, P.; Lechner, P.; Yun, J. S.; Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/ db transgenic mice. J. Biol. Chem. 1997, 272 (50), 31475-31481.
21. Gettys, T. W.; Watson, P. M.; Taylor, L. L. RU-486 (mifepristone) ameliorates diabetes but does not correct deficient beta-adrenergic signaling in adipocytes from mature C57BL/6J-ob/ob mice. Int. J. Obes. Relat. Metab. Disord. 1997, 21, 865-873.
22. Garrel, D. R.; Moussali, R.; De Oliveira, A.; Lesiege, D.; Lariviere, F. RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism. J. Clin. Endocrinol. Metab. 1991, 80(2), 379-385.
23. von Geldem, T. W.; Tu, N.; Kym, P. R.; Link, J. T.; Jae, H-S.; Lai, C.; Apelqvist, T.; Rhonnstad, P.; Hagberg, L.; Koehler, K.; Grynfarb, M.; Goos-Nilsson, A.; Sandberg, J.; Österlund, M.; Barkhem, T.; Höglund, M.; Wang, J.; Fung, S.; Wilcox, D.; Nguyen, P.; Jakob, C.; Hutchins, C.; Färnegärdh, M.; Kauppi, B.; Öhman, L.; Jacobson, P. B. Liver-Selective Glucocorticoid Antagonists: A Novel Treatment for Type 2 Diabetes. J. Med. Chem. 2004, 47, 4213-4230.
24. Link, J. T.; Sorensen, B.; Patel, J.; Grynfarb, M.; Goos-Nilsson, A.; Wang, J.; Fung, S.; Wilcox, D.; Zinker, B.; Nguyen, P.; Hickman, B.; Schmidt, J. M.; Swanson, S.; Tian, Z.; Reisch, T. J.; Rotert, G.; Du, J.; Lane, B.; von Geldern, T. W.; Jacobsen, P. B. Antidiabetic Activity of Passive Nonsteroidal Glucocorticoid Receptor Modulators. J. Med. Chem. 2005, 48, 5295-5304.
25. Bray, G. Y. D. Neuroendocrine control of the development of obesity: understanding gained from studies of experimental animal models. Front. Neuroendocrinol. 1990, 11, 128-181.
26. Langley, S. C.; York, D. A. Effects of antiglucocorticoid RU 486 on development of obesity in obese fa/fa Zucker rats. Am. J. Physiol. 1990, 259, 539-544.
27. Okada, S.; York, D. A.; Bray, G. A. Mifepristone (RU 486), a blocker of type II glucocorticoid and progestin receptors, reverses a dietary form of obesity. Am. J. Physiol. 1992, 262, 1106-1110.
28. Beebe, K. L.; Block, T.; DeBattista, C.; Blasey, C.; Belanoff, J. K. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats. Behav. Brain Res. 2006, 171, 225-229.
29. R) or mifepristone alone (p < 0.001).
30. Dhikav, V.; Anand, K. S.; Glucocorticoids may initiate Alzheimer's disease: A Potential therapeutic role for mifepristone (RU-486). Med. Hypotheses 2007, 68, 1088-1092.
31. Pomara, N.; Greenberg, W. M.; Branford, M. D.; Doraiswamy, P. M. Therapeutic implications of HPA axis abnormalities in Alzheimer's disease: Review and update. Psychopharmacol. Bull. 2003, 37, 120-134.
32. Sapolsky, R. M. Stress, the Aging Brain, and the Mechanisms of Neuron Death. Cambridge, Mass. MIT Press 1992.
33. Fuchs, E.; Flugge, G.; Stress, glucocorticoids, and structural plasticity of the hippocampus. Neurosci. Biobehav. Rev. 1998, 23, 295-300.
34. Watanabe, Y.; Gould, E.; McEwen, B. S. Stress induces atrophy of apical dendrites of hippocampal CA3 pyramidal neurons. Brain Res. 1992, 588, 341-345.
35. McEwen, B. S. The neurobiology of stress: From serendipity to clinical relevance. Brain Res. 2000, 886, 172-189.
36. Lowy, M. T.; Gault, L.; Yamamoto, B. K. Adrenalectomy attenuates stress-induced elevations in extracellular glutamate concentrations in the hippocampus. J. Neurochem. 1993, 61, 1957- 960.
37. Venero, C.; Borrell, J. Rapid glucocorticoid effects on excitatory amino acid levels in the hippocampus: A microdialysis study in freely moving rats. Eur. J. Neurosci. 1999, 11, 2465-2473.
38. Weiland, N. G.; Orchinik, M.; Tanapat, P. Chronic corticosterone treatment induces parallel changes in N-methyl-D-aspartate receptor subunit messenger RNA levels and antagonist binding sites in the hippocampus. Neuroscience 1997, 78, 653-662.
39. DeBattista, C.; Belanoff, J. C-1073 (Mifepristone) in the Adjunctive Treatment of Alzheimer's Disease. Curr. Alzheimer Res. 2005, 2, 125-129.
40. Csernansky, J. G.; Dong, H.; Fagan, A. M.; Wang, L.; Xiong, C.; Holtzman, D. M.; Morris, J. C. Plasma Cortisol and Progression of Demential in Subjects With Alzheimer-Type Dementia. Am. J. Psychiatry 2006, 163, 2164-2169.
41. Pomara, N.; Doraiswamy, P.; Murali, P. Mifepristone (RU 486) for Alzheimer's disease. Neurology 2002, 58, 1436-1439.
42. Wang, S.; Lim, G.; Zeng. Q.; Sung, B.; Ai, Y.; Guo, G.; Yang, L.; Mao, J. Expression of Central Glucocorticoid Receptros after Peripheral Nerve Injury Contributes to Neuropathic Pain Behaviors in Rats. J. Neurosci. 2004, 24, 8595-8605.
43. Takasaki, I.; Kurihara, T.; Saegusa, H.; Zong, S.; Tanabe, T. Effects of glucocorticoid receptor antagonists on allodynia and hyperalgesia in mouse model of neuropathic pain. Eur. J. Pharmacol. 2005, 524, 80-83.
44. Wang, S.; Lim, G.; Zeng, Q.; Sung, B.; Yang, L.; Mao J. Central Glucocorticoid Receptors Modulate the Expression and Function of Spinal NMDA Receptors after Peripheral Nerve Injury. J. Neurosci. 2005, 25, 488-495.
45. Deroche-Gamonet, V.; Sillaber, I.; Aouizerate, B.; Izawa, R.; Jaber, M.; Ghozland, S.; Kellendonk, C.; Le Moal, M.; Spanagel, R.; Schütz, G.; Tronche, F.; Piazzo, P. V. The Glucocorticoid Receptor as a Potential Target to Reduce Cocaine Abuse. J. Neurosci. 2003, 23, 4785-4790.
46. Armaly, M. F. Corticosteroid Glaucoma. In Glaucoma Vol 2, Cairns, J. E., ed. Grune and Stratton, London, 1986, 697-710.
47. Phillips, C.; Gore, S. M.; Green, K.; Cullen, P. M.; Campbell, M. Eye Drops of RU 486-6, A Peripheral Steroid Blocker, Lower Intraocular Pressure in Rabbits. Lancet 1984, 323, 767-768
48. Southren, A. L.; l'Hommedieu, D.; Gordon, G. G.; Weinstein, B. I. Intraocular hypotensive effect of a topically applied cortisol metabolite: 3α,5β-tetrahydrocortisol. Invest. Ophthalom. Vis. Sci. 1987, 28, 901-903.
49. Southren, A. L.; Wandel, T.; Gordon, G. G.; Weinstein, B. I. Treatment of glaucoma with 3α, 5β-tetrahydrocortisol: A new therapeutic modality. J. Ocul. Pharmacol. 1994, 10, 385-391
50. Masuda, J. M.; Duncan, G. R. Relation of Steroid Structure to Enzyme Induction in the Induction of Tyrosine Aminotransferase and Tryptophan Pyrrolase. J. Steroid Biochem. 1971, 2, 165-171
51. Whitfield, G. K.; Jurutka, P. W.; Haussler, C. A.; Haussler, M. R. Steroid Hormone Receptors: Evolution, Ligands, and Molecular Basis of Biologic Function. J. Cell. Biochem. Suppl. 1999, 32/ 33, 110-122.
52. Bledsoe, R. K., Montana, V. G.; Stanley, T. B.; Delves, C. J.; Apolito, C. J.; McKee, D. D.; Consler, T. G.; Parks, D. J.; Stewart, E. L.; Willson, T. M.; Lambert, M. H.; Moore, J. T.; Pearce, K. H.; Xu, H. E. Crystal Structure of the Glucocorticoid Receptor Ligand Binding Domain Reveals a Novel Mode of Receptor Dimerization and Coactivator Recognition. Cell 2002, 110, 93-105.
53. Kauppi, B.; Jakob, C.; Färnegärdh, M.; Yang, J.; Ahola, H.; Alarcon, M.; Calles, K.; Engström, O.; Harlan, J.; Muchmore, S.; Ramqvist, A.-K.; Thorell, S.; Öhman, L.; Greer, J.; Gustafsson, J.-A.; Carlstedt-Duke, J.; Carlquist, L.; The Three-dimensional Structures of Antagonistic and Agonistic Forms of the Glucocorticoid Receptor Ligand-binding Domain. J. Biol. Chem. 2003, 278, 22748-22754.
54. Karin, M. New twists in gene regulation by glucccorticoid receptor: Is DNA binding dispensable? Cell 1998, 93, 487490
55. McKay, L. I.; Cidlowski, J. A. Molecular control of immune/inflammatory responses: Interactions between nuclear factor-κ B and steroid receptor-signaling pathways. Endocr. Rev. 1999, 20, 435-459.
56. Ornate, S. A.; Tsai, S. Y.; Tsai, M. J.; O'Malley, B. W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995, 270, 1354-1357.
57. Peeters, B. W. M. M.; Tonnaer, J. A. D. M.; Groen, M. B.; Broekkamp, C. L. E.; van der Voort, H. A. A.; Schoonen, W. G. F. J.; Smets, R. J. M.; Vanderheyden, P. M. L.; Gebhard, R.; Ruigt, G. S. F. Glucocorticoid Receptor Antagonists: New Tools to Investigate Disorders Characterized by Cortisol Hypersecreation. Stress 2004, 7, 233-241.
58. Srinivasan, G.; Thompson, E. B. Overexpression of full-length human glucocorticoid receptor in Spodoptera frugiperda cells using the baculovirus expression vector system. Mol. Endocrinol. 1990, 4, 209-216.
59. Honer, C.; Nam, K.; Fink, C.; Marshall, P.; Ksander, G.; Chatelain, E.; Cornell, W.; Steele, R.; Schweitzer, R.; Schumacher, C. Glucocorticoid Receptor Antagonism by Cyproterone Acetate and RU486. Mol. Pharmacol. 2003, 63, 1012-1020.
60. Buetti, E.; Kühnel, B. Distinct sequence elements involved in the glucocorticoid regulation of the mouse mammary tumor virus promoter identified by linker scanning mutagenesis. J. Mol. Biol. 1989, 190, 379-389.
61. Granner, D.; Pilikis, S. The genes of hepatic glucose metabolism. J. Biol. Chem. 1990, 265, 10173-10176.
62. Wagner, B. L.; Pollio, G.; Giandgrande, P.; Webster, J. C.; Breslin, M.; Mais, D. E.; Cook, C. E.; Vedeckis, W. V.; Cidlowski, J. A.; McDonnell, D. P. The Novel Progesterone Receptor Antagonists RTI 3021-012 and RTI 3021-022 Exhibit Complex Glucocorticoid Receptor Antagonist Activities: Implications for the Development of Dissociated Antiprogestins. Endocrinology 1999, 140, 1449-1458.
63. Reul, J. M.; de Kloet, E. R.; van Sluijs, F. J.; Rijnberk, A.; Rothuizen, J. Binding characteristics of mineralocorticoid and glucocorticoid receptors in dog brain and pituitary. Endocrinology 1990, 127, 907-915.
64. Morgan, B. P.; Swick, A. G.; Hargrove, D. M.; LaFlamme, J. A.; Moynihan, M. S.; Carroll, R. S.; Martin, K. A.; Lee, E.; Decosta, D.; Bordner, J. Discovery of Potent, Nonsteroidal, and Highly Selective Glucocorticoid Receptor Antagonists. J. Med. Chem. 2002, 45, 2417-2424.
65. Morgan, B. P.; Liu, K. K.-C.; Dalvie, D. K.; Swick, A. G.; Hargrove, D. M.; Wilson, T. C.; LaFlamme, J. A.; Moynihan, M. S.; Rushing, M. A.; Woodworth, G. F.; Li, J.; Trilles, R. V.; Yang, X.; Harper, K. W.; Carroll, R. S.; Martin, K. A.; Nardone, N. A.; O'Donnell, J. P.; Faletto, M. B.; Vage, C.; Soliman, V. Discovery of Potent, Non-Steroidal and Highly Selective Glucocorticoid Receptor Antagonists with Anti-Obesity Activity. Lett Drug Design Discov. 2004, 1, 1.
66. Teutsch, G.; Deraedt, R.; Philibert, D. Mifepristone. Chron. Drug Discov. 1993, 3, 1-43.
67. Teutsch, G.; Qjasoo, T.; Raynaud, J. P. 11β-Substituted Steroids, An Original Pathway to Antihormones. J. Steroid Biochem. 1988, 31, 549-565.
68. Teutsch, G.; Gaillard-Moguilewsky, M.; Lemoine, G.; Nique, F.; Philibert, D. Design of ligands for the glucocorticoid and progestin receptors. Biochem. Soc. Trans. 1991, 19, 901-908
69. Philibert, D.; Costerousse, G.; Gaillard-Moguilewsky, M.; Nedelec, L.; Nique, F.; Tournemine, C.; Teutsch, G. From RU 38486 towards Dissociated Antiglucocorticoid and Antiprogesterone. Front. Horm. Res. 1991, 19, 1-17.
70. Teutsch, G.; Nique, F.; Lemoine, G.; Bouchoux, F.; Cerede, E.; Gofflo, D.; Philibert, D. General Structure-Activity Correlations of Antihormones. Ann. N. Y. Acad. Sci. 1995, 76, 5-28.
71. Ottow, E.; Neef, G.; Wiechert, R. Stereo- and Regiospecific 6- endo-trig-Cyclization of Aryl Radicals, an Entry to Novel Progesterone-Antagonists of the Androstane Series. Angew. Chem. Int. Ed. Engl. 1989, 28, 773-776.
72. Ottow, E.; Beier, S.; Elger, W.; Fritzemeier, K.-H.; Neef, G.; Wiechert, R. Synthesis and biological testing of 4′-(dimethyl-amino) 17β-hydroxy-17α-(i-propynyl)benzo[12,12a]- 11α,18-cyclo-12a,12b-dihomo-13 α-estr-4-en-3-one: An interesting RU 38 486 analog. Steroids 1994, 59, 185-189.
73. Gebhard, R., van der Voort, H.; Schuts, W.; Schoonen, W. 11,21-Bisphenyl-19-norpregnane derivatives are selective antiglucocorticoids. Bioorg. Med. Chem. Lett. 1997, 7, 2229-2234.
74. Bachmann, C. G.; Linthorst, A. C. E.; Holsboer, F.; Reul, J. M. H. M. Effect of Chronic Administration of Selective Glucocorticoid Receptor Antagonists on the Rat Hypothalamic-Pituitary-Adrenocortical Axis. Neuropsychopharmocol. 2003, 28, 1056-1067.
75. Richards, S. J.; von Geldern, T. W.; Jacobson, P., Wilcox, D.; Nguyen P.; Öhmann, L.; Österlund, M.; Gelius, B.; Grynfarb, M.; Goos-Nilsson, A.; Wang, J.; Fung, S.; Kalmanovich, M. Synthesis and activity of novel bile-acid conjugated glucocorticoid receptor antagonists. Bioorg. Med. Chem. Lett. 2006, 16, 6086-6090.
76. Link, J. T.; Sorenson, B. K,; Lai, C.; Wang, J.; Fung, S.; Deng, D.; Emery, M.; Carroll, S.; Grynfarb, M.; Goos-Nilsson, A.; von Geldern, T. Synthesis, activity, metabolic stability, and pharmacokinetics of glucocorticoid receptor modulator-statin hybrids. Bioorg. Med. Chem. Lett. 2004, 14, 4173-4178.
77. Backes, B. J.; Hamilton, G. L.; Nguyen, P.; Wilcox, D.; Fung, S.; Wang, J.; Grynfarb, M.; Goos-Nilsson, A.; Jacobson, P. B.; von Geldem, T. W. Parallel strategies for the preparation and selection of liver-targeted glucocorticoid receptor antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 40-44.
78. Hamilton, G. L.; Backes, B. J. Synthesis of C-11 modified mifepristone analog libraries. Mol. Divers. 2007, 11, 107-111
79. Sorenson, B. K.; Link, J. T.; von Geldern, T.; Emery, M.; Wang, J.; Hickman, B.; Grynfarb, M.; Goos-Nilsson, A.; Carroll, S. An Evaluation of a C-Glucoronide 1 as a Liver Targeting Group: Conjugate of a Glucocorticoid Antagonist. Bioorg. Med. Chem. Lett. 2003, 13, 2307-2310.
80. Jiang, W.; Fiordeliso, J. J.; Allan, G.; Linton, O.; Tannenbaum, P.; Xu, J.; Zhu, P.; Gunnet, J.; Demarest, K.; Lundeen, S.; Sui, Z. Discovery of novel phosphorous-containing steroids as selective glucocorticoid receptor antagonist. Bioorg. Med. Chem. Lett. 2007, 17, 1471-1474.
81. Morgan, B.; Selective glucocorticoid receptor modulators, in: Proceedings of the Gordon Conference on Medicinal Chemistry, Colby Sawyer College, New London, NH, 2001.
82. Murry, J. A.; White, T. D. Eur. Patent Application 1201655A2 (2001).
83. Chantigny, Y. A.; Kleinman, E. F.; Robinson, R. P. Jr. PCT Patent WO005229 (2004).
84. Einstein, M.; Greenlee, M.; Rouen, G.; Sitlani, A.; Santoro, J.; Wang, C.; Pandit, S.; Mazur, P.; Smalera, I.; Weaver, A. P. M.; Zeng, Y. Y.; Ge, L.; Kelly, T.; Paiva, T.; Geissler, W.; Mosley, R. T.; Williamson, J.; Ali, A.; Balkovec, J.; Harris, G. Selective glucocorticoid receptor nonsteroidal ligands completely antagonize the dexamethasone mediated induction of enzymes involved in gluconcogenesis and glutamine metabolism. J. Steroid Biochem. Mol. Biol. 2004, 92, 345-356.
85. Minor, J. N.; Tyree, C.; Hu, J.; Berger, E.; Marshke, K.; Nakane, M.; Coghlan, M. J.; Clemm, D.; Lane, B.; Rosen, J. A Nonsteroidal Glucocorticoid Receptor Antagonist. Mol. Endocrinol. 2003, 17, 117-127.
86. Coghlan, M. J.; Luly, J. R.; Schkeryantz, J. M.; Wang, A. X. U.S. Patent 6166013 (2000).
87. Apelqvist, T.; Efendic, S. PCT Patent WO/9963976 (1999).
88. Coghlan, M. J.; Jacobson, P. B.; Lane, B.; Nakane, M.; Lin, C. W.; Elmore, S. W.; Kym, P. R.; Luly, J. R.; Carter, G. W.; Turner, R.; Tyree, C. M.; Hu, J.; Elgort, M.; Rosen, J.; Miner, J. N. A novel anti-inflammatory maintains glucocorticoid efficacy with reduced side effects. Mol. Endocrinol. 2003, 17, 860-869.
89. Akritopolou-Zanze, I.; Patel, J. R.; Hartandi, K.; Brenneman, J.; Winn, M.; Pratt, J. K.; Grynfarb, M.; Goos-Nilsson, A.; von Geldern, T. W.; Kym, P. R. Synthesis and biological evaluation of novel, selective, nonsteroidal glucocorticoid receptor antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 2079-2082.
90. Link J. T.; Sorensen, B. K.; Patel, J.; Emery, M.; Grynfarb, M.; Goos-Nilsson, A. Discovery of novel nonsteroidal glucocorticoid receptor modulators. Bioorg. Med. Chem. Lett. 2004, 14, 2209-2212.
91. Link, J. T.; Sorensen, B. K.; Patel, J.; Arendsen, D.; Li, G.; Swanson, S.; Nguyen, B.; Emery, M.; Grynfarb, M.; Goos-Nilsson, A. Optimization and metabolic stabilization of a class of nonsteroidal glucocorticoid modulators. Bioorg. Med. Chem. Lett. 2004, 14, 4169-4172.
92. Tu, N.; Link J. T.; Sorensen, B. K.; Emery, M.; Grynfarb, M.; Goos-Nilsson, A.; Nguyen, B. Bile acid conjugates of a nonsteroidal glucocorticoid receptor antagonist. Bioorg. Med. Chem. Lett. 2004, 14, 4179-4183.
93. Takahashi, H.; Bekkali, Y.; Capolino, A. J.; Gilmore, T.; Goldrick, S. E.; Nelson, R. M.; Terenzio, D.; Wang, J.; Zuvela-Jelaska, L.; Proudfoot, J.; Nabozny, G.; Thomson, D. Discovery and SAR study of novel dihydroquinoline containing glucocorticoid receptor ligands. Bioorg. Med. Chem. Lett. 2006, 16, 1549-1552.
94. Ray, N. C.; Clark, R. D.; Clark, D. E.; Williams, K.; Hickin, H. G.; Crackett, P. H.; Dyke, H. J.; Lockey, P. M.; Wong, M.; Devos, R.; White, A.; Belanoff, J. K. Discovery and optimization of novel, non-steroidal glucocorticoid receptor modulators. Bioorg. Med. Chem. Lett. 2007, 17, 4901-4905.
95. Clark R. D.; Ray, N. C.; Blaney, P.; Crackett, P. H.; Hurley, C.; Williams, K.; Dyke, H. J.; Clark, D. E.; Lockey, P. M.; Davos, R.; Wong, M.; White, A.; Belanoff, J. K. 2-Benzenesulfonyl-8a- benzyl-hexahydro-2H-isoquinolin-6-ones as selective glucocorticoid receptor antagonists. Bioorg. Med. Chem. Lett. 2007, 17, 5704-5708.
96. 6-Hydrocortisone and Related Compounds. J. Am. Chem. Soc. 1963, 85, 236.
97. Hirschmann, R.; Steinberg, N. G.; Buchschacher, P.; Fried, J. H.; Kent, G. J.; Tishler, M. Synthesis and Structures of Steroidal 4- Pregneno[2,3-c]pyrazoles. A Novel class of Potent Antiinflammatory Steroids. J. Am. Chem. Soc. 1963, 85, 120.
98. Shah, N.; Scanlan, T. S. Design and evaluation of novel nonsteroidal dissociating glucocorticoid receptor ligands. Bioorg. Med. Chem. Lett. 2004, 14, 5199.
99. Ali, A.; Thompson,. C. F.; Balkovec, J. M.; Graham, D. W.; Hammond, M. L.; Quraishi, N.; Tata, J. R.; Einstein, M.; Ge, L.; Harris, G.; Kelly, T. M.; Mazur, P.; Pandit, S.; Santoro, J.; Sitlani, A.; Wang, C.; Williamson, J.; Miller, D. K.; Thompson, C. M.; Zaller, D. M.; Forrest, M. J.; Carballo-Jane, E.; Luell, S. Novel N- Arylpyrazolo[3,2-c]-Based Ligands for the Glucocorticoid Receptor: Receptor Binding and in vivo Activity. J. Med. Chem. 2004, 47, 2441-2452.
100. Clark, R. D.; Ray N. C.; Williams, K.; Blaney, P.; Ward, S.; Crackett, P. H.; Hurley, C.; Dyke, H. J.; Clark, D. E.; Lockey, P.; Devos, R.; Wong, M.; Porres, S. S.; Bright, C. P.: Jenkins,. R. E.; Belanoff, J. 1H-Pyrazolo[3,4-g]hexahydro-isoquinolines as selective glucocorticoid receptor antagonists wit high functional activity. Bioorg. Med. Chem. Lett. 2008, 18, 1312-1317.